Results 71 to 80 of about 4,412 (151)
Efficacy and safety of COVID-19 vaccines [PDF]
Background: Different forms of vaccines have been developed to prevent the SARS-CoV-2 virus and subsequent COVID-19 disease. Several are in widespread use globally.
Askie, Lisa M. +29 more
core +2 more sources
ABSTRACT Background Coronavirus disease 2019 (COVID‐19) is a lethal global pandemic that originated in Wuhan, China at the end of 2019. As with other viral infectious diseases, the introduction of an effective vaccine is crucial for stopping the spread of the pandemic. In Iraq the COVID‐19 vaccination campaign started on March 2, 2021.
Ahmed Hakim Al‐Obaidi +2 more
wiley +1 more source
Challenging the focus on age, this study finds pre‐existing T helper 1 cells are the key biomarker for predicting antibody response to SARS‐CoV‐2 inactivated vaccines. In both mice and humans, high responders exhibited elevated baseline T helper 1 cells, which correlated with robust humoral immunity, offering crucial guidance for improving vaccine ...
Chanyuan Ye +12 more
wiley +1 more source
To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco.
Karima Abounouh +18 more
doaj +1 more source
Myelitis, including longitudinally extensive transverse myelitis (LTEM), is reported in more than forty patients after coronavirus disease 2019 (COVID-19).
Mahsa Sepahvand, MD +3 more
doaj +1 more source
Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials [PDF]
Although over 13 billion COVID-19 vaccine doses have been administered globally, the issue of whether the optimal doses are being used has received little attention.
Dunn, David T +3 more
core
ABSTRACT The COVID‐19 pandemic highlights the need for mucosal vaccines inducing respiratory secretory IgA (sIgA), as traditional intramuscular vaccines primarily elicit systemic IgG with limited mucosal protection. This study systematically compared mucosal immune responses induced by two authorized COVID‐19 mucosal vaccines: an orally aerosolized ...
Weixin Chen +10 more
wiley +1 more source
ABSTRACT Vaccine‐induced thrombotic thrombocytopenia (VITT) has been linked to vector‐based vaccines, but only four cases following whole‐virus vaccines (Sinopharm) have been reported, as far as we are aware. This systematic review aimed to compile the clinical and laboratory results of VITT development after Sinopharm vaccination.
Shafi Rehman +5 more
wiley +1 more source
Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma [PDF]
Coronavirus disease 2019 (COVID-19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID-19 hyperimmune globulin (COVID-HIG), a passive immunotherapy, is prepared from the plasma of healthy
Deng, Kun +33 more
core +1 more source
Herpetic anterior uveitis following COVID-19 vaccines: a case series. [PDF]
PURPOSE To report a case series of herpetic uveitis following COVID-19 vaccinations. METHODS Demographic, clinical and treatment-related data of herpetic anterior uveitis cases was collected at five tertiary eye hospitals between January 2021 ...
Agarwal, Aniruddha +9 more
core +2 more sources

